

Q2 and H1 2017 Results

DIASORIN SPA August 3, 2017



The Diagnostic Specialist

Disclaimer

These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation relating to the Company.

Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those expressed in or implied by these forward-looking statements as a result of various factors, many of which are beyond the ability of DiaSorin S.p.A. to control or estimate precisely. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange.

Piergiorgio Pedron, the Officer Responsible for the preparation of corporate financial reports of **DiaSorin S.p.A.**, in accordance with the second subsection of art. 154-bis, part IV, title III, second paragraph, section V-bis, of Legislative Decree February 24, 1998, no. 58, declares that, to the best of his knowledge, the financial information included in the present document corresponds to book of accounts and book-keeping entries of the Company.

Overview

Siemens ELISA Immunodiagnostic business portfolio acquisition

Highlights

Q2 and H1 '17 Main Topics Revenues

- Breakdown by Technology
- Breakdown by Geography Installed Base Expansion

Profitability Profile

14

16

4

8

FY 2017 Company Guidance

Annex

Siemens ELISA Immunodiagnostic business portfolio acquisition

Siemens ELISA Immunodiagnostic business portfolio acquisition



TARGET DESCRIPTION	Siemens ELISA products are manufactured in one plant based in Germany and are marketed through direct network and independent distributors in:	 hospitals private laboratories blood banks
ASSET DEAL	Customers portfolio & commercial contracts:	 Significant customers base (most viable for swap to Liaison XL+XS) Main geographies: Europe + some non-European countries, ex US
	Siemens ELISA relevant business brands, industrial intellectual property & warehouse of finished products and spare parts	► transferred
	DiaSorin to exclusively distribute the acquired Siemens ELISA business for the next 3 years	

	Blood banks			HIV 🥝 Treponema 🥝		✓1/2 	
_			0			1/2	
	Infectivity line	Toxoplasma		Borreliosis	0	Mumps	0
Brance		Toxo Avidity CMV ©		H. Pylori Ab Bord. Pert. Toxin		Measles Varicella Zoster	_
		CMV Avidity HSV 1-2 lgG		Chlam. Trachom. Myco. Pneum.	v	EBV Parvovirus B 19	v
		HSV 1-2 IgM	~	Chagas	v	Rubella	0

The rationale of the acquisition

A PERFECT FIT WITH THE BUSINESS EXPECTATIONS

ELISA BUSINESS OVERLAP WITH EXISTING CLIA MENU AVAILABLE ON LIAISON PLATFORMS

Conversion of the existing Siemens ELISA products offer to DiaSorin's LIAISON offer (CLIA technology), leveraging on the menu overlap between the 2 different technologies

NEW CUSTOMERS BASE AVAILABLE

Siemens ELISA products sold to a significant customers base, mainly in Europe; most of them perfectly fit with the current LIAISON XL and the future LIAISON XS strategy, with cross-selling opportunities

EUROPEAN MARKET SHARE

Access to a qualified customer base: mainly Europe + some key non-European markets (ex US). Increase of DiaSorin penetration with LIAISON products, leveraging on Siemens' starting customers list

STRENGTHENING OF THE INFECTIOUS DISEASES OFFER

DiaSorin strengthening its positioning as a key player in the Infectious Diseases market











Figures and financing		DiaSorin 11-Diagnosic Speculist
FINANCIAL FIGURES	FY 2016 revenues as of Sept 30, 2016	► € 47 million
	EBITDA margin expected (*) during the next 3 years	in line with DiaSorin Group profitability
FINANCING	Price of the transaction	The price for the transaction is up to a maximum of € 47.5 million on a debt free cash free basis
	Funding	The cash transaction will be funded through available cash
	Accretion to DiaSorin EPS	The transaction is expected to be immediately accretive to DiaSorin's ongoing earnings per share upon close

(*) DiaSorin managerial estimates



Q2 and H1 '17 main topics

	Q2'17	H1'17
REVENUES	€/min 161.8 ^(*)	€/min 319.3 (*)
	+14.2% @ CER +13.2%	+19.9% @ CER +18.3%
CLIA ex Vit D 25 OH	+12.4% @ CER +12.1%	+12.3% @ CER +11.5%
Vit D 25 OH	+3.4% @ CER 1.6%	+3.3% @ CER 0.8%
Евітда	€/mln 63.7	€/min 126.2
	+15.6% @ CER +15.6%	+23.4% @ CER +22.3%
EBITDA MARGIN	39.4% +50 bps	39.5% +110 bps
NET RESULT	€/mln 33.6	€/mln 66.4
	+14.4%	+22.9%
% OF REVENUES	20.7%	20.8%
FCF	€/min 17.4	€/min 61.0
	-€/mln 8.1	+€/min 7.1
NFP		+€/min 89.2
		+€/mln 18.1

 Q2'17
 H1'17
 @ Jun 30, 2017

 LIAISON & LIAISON XL PLACEMENTS
 +185
 +370
 3,233

 LIAISON XL
 -23
 -35
 3,964

 TOTAL
 +162
 +335
 7,197

Product Develop	ment	
IMMUNO		MOLECULAR
Endocrinology	Androstenedione	Onco-haematology CBFB-MYH11
	► SHBG	

Business Development

QIAGEN AGREEMENT

DiaSorin to expand its LIAISON tests menu through adoption of selected QIAGEN assays

TECAN AGREEMENT

DiaSorin to use customized version of Tecan's Fluent[®] Laboratory Automation Solution as its Nucleic Acid extraction platform in combination with Simplex 96 well discs

SIEMEN ELISA Immunodiagnostic business portfolio acquisition

*Revenues includes the contribution of DiaSorin Molecular's business, consolidated as of May 2016

		Q2'17 vs. Q2'16	H1'17 vs. H1'16
	@ current	+14.2%	+19.9%
Revenues	@ CER	+13.2%	+18.3%

(*) Revenues includes the contribution of DiaSorin Molecular's business, consolidated as of May 2016

Growth driven by


- **all CLIA tests**, net of Vitamin D 25 OH, with particular evidence on:
 - Infectious Diseases
 - Hepatitis
 - Endocrinology
 - Gastro-Intestinal Testing
 - Vitamin D 1,25
- molecular tests (different scope of consolidation)
- flat Vitamin D


Positive performance of all geographies

Forex positive impact = + €/mln 4.3










(*) Revenues includes the contribution of DiaSorin Molecular's business, consolidated as of May 2016



Revenues (*): breakdown by technology

			Q2'17 VS. Q2'16	H1'17 VS. H1'16
	CLIA ex Vitamin D	@ current	+12.4%	+12.3%
CLIA	25 OH tests	@ CER	+12.1%	+11.5%
С	Vitamin D	@ current	+3.4%	+3.3%
	25 OH test (CLIA)	@ CER	+1.6%	+0.8%
	ELISA tests	@ current	+2.4%	+10.2%
	LLIOA (6313	@ CER	+0.9%	+8.0%
	Molecular Diagnostic tests	€ / mln	12.5	30.8
	Instruments &	@ current	+20.7%	+23.1%
	Consumables	@ CER	+20.6%	+22.2%

(*) Revenues includes the contribution of DiaSorin Molecular's business, consolidated as of May 2016



Revenues (*): breakdown by geography

(*) Managerial outlook on data reported; Change H1'17 on H1'16 @ CER; Revenues includes the contribution of DiaSorin Molecular's business, consolidated as of May 2016

Q2 and H1 2017 Results Presentation

DiaSorin

Revenues (*): breakdown by geography



H1'17

Central and South America:


7.3%

North America:

32.4%

Asia Pacific:

17.6%



(*) Revenues includes the contribution of DiaSorin Molecular's business, consolidated as of May 2016


Revenues (*): breakdown by geography



Growth mainly driven by Vitamin D 1,25, Gastro-Intestinal testing and Infectious Disease panel.

Italy	+5.3%	+3.2%				
Increase in Gastro-Intestinal testing, Infectious Diseases panel, PCT and Vitamin D 1,25. Positive variance also for Vitamin D 25 OH.						
France	+4.0%	+5.7%				
Continuous increase in CLIA ex Vi	Continuous increase in CLIA ex Vit. D 25 OH tests (+6.5% vs. H1'16)					
NORTH AMERICA	+20.7%	+37.7%				
USA	+21.0%	+38.1%				

Increase in CLIA ex Vit. D 25 OH panels driven by Infectious Diseases, Endocrinology, pre- natal screen panel and Vitamin D 1,25. Different perimeter of consolidation (DiaSorin Molecular positive contribution).



Growth in CLIA tests driven by Hepatitis, Endocrinology and Infectious Diseases panel.

Dis	tributors	+0.2%	-5.9%

Performance affected by RIA technology discontinuation and slowdown of some middle-east markets.

LATIN AMERICA	-0.2%	+12.6%
Brazil	+15.5%	+18.4%

Positive performance of CLIA ex Vit. D 25 OH tests driven by Hepatitis, Infectious Diseases, Endocrinology and Vitamin D 1,25. Good performance of Murex Elisa

Rising performance driven by Infectious Diseases and Hepatitis panels.

(*) Managerial outlook on data reported; Change QoQ and HoH @ CER; Revenues includes the contribution of DiaSorin Molecular's business, consolidated as of May 2016

	Units at December 31, 2016	Net placements in H1 2017	Units at June 30, 2017
LIAJSON	3,999	-35	3,964
LIAJSON®	2,863	+370	3,233
TOTAL	6,862	+335	7,197

Installed base expansion



16



Profitability Profile



Increase compared to H1'16, mainly driven by:

• Higher sales, due to

- change in scope of consolidation;
- sound growth of immunodiagnostic products, mainly driven by CLIA ex Vitamin D.
- Operational leverage driven by a tight cost control, some positive phasing and lower Non recurring expenses

FY 2017 Company Guidance

FY 2017 Company Guidance




FY 2017 Company Guidance, not including ELISA business acquisition from Siemens^(*)

Revenues	Growth equal to around +11% at CER compared with 2016 (**) (No changes compared to Previous guidance)
EBITDA	Growth equal to around +13% at CER compared with 2016 (**) (Previous guidance: Growth equal to around +11% at CER compared with 2016 (**))


(*) closing expected in H2 2017 (**) 2016 EUR/US\$ exchange rate = 1.11



Q2'17 results: Income Statement



H1'17 results: Income Statement





H1'17 results: Balance Sheet



Data in € million	12/31/2016	6/30/2017	Change
Goodwill and intangibles assets	357.1	331.5	-25.6
Property, plant and equipment	92.1	88.4	-3.7
Other non-current assets	24.0	24.7	+0.7
Net working capital	165.0	176.4	+11.4
Other non-current liabilities	-46.1	-47.8	-1.7
Net Invested Capital	592.2	573.2	-19.0
Net Financial Position	71.2	89.2	+18.1
Total Shareholders' equity	663.4	662.4	-1.0

Q2'17 results: Cash Flow Statement



Data in € million	Q2		Change
	2016	2017	Change
Cash and cash equivalents at the beginning of the period	292.1	172.8	-119.4
Cash provided by operating activities	34.3	25.8	-8.5
Cash used in investing activities	-8.7	-9.1	-0.4
Cash provided/(used) in financing activities	17.9	-59.4	-77.3
Acquisitions of companies and business operations	-262.4	-1.0	+261.5
Net change in cash and cash equivalents before investments in financial assets	-218.9	-43.7	+175.2
Divestment/(Investments) in financial assets	-	-21.1	-21.1
Net change in cash and cash equivalents	-218.9	-64.8	+154.1
Cash and cash equivalents at the end of the period	73.2	107.9	+34.7

H1'17 results: Cash Flow Statement



Data in € million	H1		Change
	2016	2017	Change
Cash and cash equivalents at the beginning of the period	212.2	130.5	-81.7
Cash provided by operating activities	68.1	77.0	8.8
Cash used in investing activities	-14.5	-17.1	-2.6
Cash provided/(used) in financing activities	12.8	-60.2	-73.0
Acquisitions of companies and business operations	-262.4	-1.1	261.4
Net change in cash and cash equivalents before investments in financial assets	-196.0	-1.4	194.6
Divestment/(Investments) in financial assets	57.0	-21.1	-78.1
Net change in cash and cash equivalents	-139.0	-22.5	116.4
Cash and cash equivalents at the end of the period	73.2	107.9	34.7

